CELLDEX THERAPEUTICS INC (CLDX:NASDAQ)
$29.89 0.59 (2.0137%)
Analysed CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) News Sources
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
24-07-2026
yahoo.com
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
06-08-2026
yahoo.com
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return
09-08-2026
yahoo.com
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
09-08-2026
yahoo.com
Celldex to Present at Upcoming Investor Conference
08-09-2026
yahoo.com
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
22-09-2026
yahoo.com
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
22-09-2026
advfn.com
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
22-09-2026
marketbeat.com
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
22-09-2026
stocktwits.com
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
23-09-2026
yahoo.com
What is the current price of CELLDEX THERAPEUTICS INC (CLDX:NASDAQ)?
The current price of CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) is $29.89.
CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) since the previous trading day is $0.59.
CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) since the previous trading day is 2.0137%.
What is the most recent average sentiment score for CELLDEX THERAPEUTICS INC (CLDX:NASDAQ)?
The most recent average sentiment score for CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for CELLDEX THERAPEUTICS INC (CLDX:NASDAQ)?
The most recent sentiment for CELLDEX THERAPEUTICS INC (CLDX:NASDAQ) is .
SEC-8K** Filing Available For CELLDEX THERAPEUTICS INC (CLDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.